PMV Pharmaceuticals, Inc. PMVP
Set alert
As of Nov 2, 11:18 AM ET
- YTD
- +8.80%
- 1 year
- -3.55%
- Open
- 1.33
- Prev close
- 1.31
- Mkt cap
- 102.70M
- Vol
- 263.05K
- Avg vol
- 686.55K
- EPS
- -1.42
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.33
- High
- 1.40
- Forward P/E
- -0.96
- Beta
- 1.48
- Short ratio
- 5.17
- Inst. own
- 83.89%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 1.61
- 200-d avg
- 1.65
- 1y target
- 5.80
News
2 weeks ago zacks.com
PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know
PMV Pharmaceuticals gains on promising rezatapopt data in ovarian cancer, FDA support for accelerated approval and a planned 2027 NDA filing.
3 weeks ago seekingalpha.com
PMV Pharmaceuticals: Restoring Mutant P53 Could Create A Mispriced Cancer Opportunity
PMV Pharmaceuticals is rated Buy, targeting $3–$4/share, driven by rezatapopt's 46% response rate and 10-month median duration in Y220C-mutant ovarian cancer. PMVP's medicinal chemistry leverages the…
1 month ago defenseworld.net
PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Stock Has Consensus Target Price of $4.33 According to Analysts
PMV Pharmaceuticals, Inc. (NASDAQ: PMVP - Get Free Report) has been given a consensus rating of "Moderate Buy" by the five research firms that are covering the company, MarketBeat.com reports. One…
1 month ago zacks.com
Should You Buy PMV Pharmaceuticals, Inc. (PMVP) After Golden Cross?
PMV Pharmaceuticals, Inc. (PMVP) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, PMVP's 50-day simple moving average crossed…
2 months ago benzinga.com
PMV Pharma Raises $50.8 Million to Fuel Cancer Drug Push
PMV Pharmaceuticals reports 46% ORR in Phase 2 trial for ovarian cancer drug rezatapopt. NDA submission planned for Q1 2027.
2 months ago benzinga.com
Why Pyxis Tankers Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket
Shares of Pyxis Tankers Inc (NASDAQ:PXS) rose sharply in pre-market trading after the company reported better-than-expected earnings for the second quarter. The company posted quarterly earnings of…
2 months ago globenewswire.com
PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities
PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of…
2 months ago globenewswire.com
PMV Pharma Announces Proposed Public Offering of Securities
PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of…
2 months ago globenewswire.com
PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial
PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of…
2 months ago zacks.com
PMV Pharmaceuticals (PMVP) Upgraded to Buy: What Does It Mean for the Stock?
PMV Pharmaceuticals (PMVP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
-
2 months ago benzinga.com
PMV Pharma Q2 EPS $(0.34) Beats $(0.39) Estimate
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.39) by 12.82 percent. This is a 17.07 percent increase over losses of $(0.41)…
2 months ago globenewswire.com
PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights
PRINCETON, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of…
4 months ago zacks.com
PMV Pharmaceuticals (PMVP) Upgraded to Buy: Here's Why
PMV Pharmaceuticals (PMVP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
4 months ago zacks.com
PMV Pharmaceuticals (PMVP) Loses 26% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
PMV Pharmaceuticals (PMVP) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising…
5 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
5 months ago benzinga.com
Oppenheimer Maintains Outperform on PMV Pharmaceuticals, Lowers Price Target to $5
Oppenheimer analyst Jeff Jones maintains PMV Pharmaceuticals (NASDAQ:PMVP) with a Outperform and lowers the price target from $6 to $5.
-
5 months ago benzinga.com
PMV Pharma Q1 EPS $(0.34) Beats $(0.39) Estimate
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.39) by 12.82 percent. This is unchanged from the same period last year.
-
6 months ago benzinga.com
PMV Pharmaceuticals Appoints Laurie Stelzer As Board Chair, Effective June 4, Succeeding Rich Heyman
PMV Pharmaceuticals, Inc. ("PMV Pharma" or the "Company"; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today…
6 months ago globenewswire.com
PMV Pharmaceuticals Announces Board Chair Transition
Rich Heyman to retire from PMV Pharma Board of Directors; Laurie Stelzer, Director since 2020, appointed as new Chair Rich Heyman to retire from PMV Pharma Board of Directors; Laurie Stelzer,…
-
8 months ago benzinga.com
PMV Pharma Q4 EPS $(0.34) Beats $(0.41) Estimate
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.41) by 16.46 percent. This is a 24.44 percent increase over losses of $(0.45)…
8 months ago globenewswire.com
PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights
PRINCETON, N.J., March 06, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of…
8 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
-
8 months ago benzinga.com
PMV Pharmaceuticals Announces NEJM Publication Showing Phase 1 Rezatapopt Demonstrates Safety And Antitumor Activity In TP53 Y220C–Mutated Cancers
PMV Pharmaceuticals, Inc. (("PMV Pharma" or the "Company", NASDAQ:PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today…
11 months ago defenseworld.net
PMV Pharmaceuticals (NASDAQ:PMVP) versus Aurinia Pharmaceuticals (NASDAQ:AUPH) Financial Comparison
Aurinia Pharmaceuticals (NASDAQ: AUPH - Get Free Report) and PMV Pharmaceuticals (NASDAQ: PMVP - Get Free Report) are both medical companies, but which is the better business? We will contrast the…
-
11 months ago benzinga.com
PMV Pharma Q3 EPS $(0.40), Inline
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.40) per share which met the analyst consensus estimate. This is a 8.11 percent decrease over losses of $(0.37) per share from the same period…
-
1 year ago benzinga.com
PMV Pharmaceuticals Announces Updated Data From The Phase 2 Pivotal Portion Of The Ongoing PYNNACLE Clinical Trial In Patients With Advanced Solid Tumors Harboring A TP53 Y220C Mutation; Overall Response Rate Of 34% (35/103 Patients) Per Investigator Assessment According To Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1, Including Confirmed And Unconfirmed Responses
Data presented today as an oral presentation at 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Confirmed responses observed in eight tumor types spanning…
1 year ago globenewswire.com
PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
PRINCETON, N.J., Oct. 24, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of…
-
1 year ago benzinga.com
PMV Pharmaceuticals To Present Rezatapopt Pivotal Phase 2 Initial Analysis And Natural History Study Results
PMV Pharmaceuticals to Present Rezatapopt Pivotal Phase 2 Initial Analysis and Natural History Study Results at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer…
1 year ago benzinga.com
Small-Cap PMV Pharmaceuticals Cancer Drug Shows Confirmed Responses In 8 Tumor Types
PMV Pharmaceuticals, Inc. PMVP on Wednesday released interim data from the Phase 2 pivotal portion of the PYNNACLE clinical trial evaluating rezatapopt in patients with advanced solid tumors…
1 year ago benzinga.com
Small-Cap PMV Pharmaceuticals Cancer Drug Shows Confirmed Responses In 8 Tumor Types
PMV Pharma's Phase 2 trial shows 33% response in TP53 Y220C-mutated tumors, with ovarian cancer achieving a 43% response rate in interim results.
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
-
1 year ago benzinga.com
PMV Pharma Announces Interim Data From Phase 2 Pivotal Portion Of PYNNACLE Clinical Trial; Plans To Submit NDA For Platinum Resistant/Refractory Ovarian Cancer By End Of Q1 2027
PYNNACLE Phase 2 pivotal clinical trial interim data include confirmed responses observed in eight tumor types spanning ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and…
1 year ago globenewswire.com
PMV Pharmaceuticals Announces Promising Rezatapopt Monotherapy Interim Data From PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation
PRINCETON, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of…
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
1 year ago fool.com
PMV Pharmaceuticals (PMVP) Q2 Loss Jumps
PMV Pharmaceuticals (PMVP) Q2 Loss Jumps
-
1 year ago benzinga.com
PMV Pharma Q2 EPS $(0.41) Misses $(0.38) Estimate
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.41) per share which missed the analyst consensus estimate of $(0.38) by 7.05 percent. This is a 1950 percent decrease over losses of $(0.02)…
1 year ago globenewswire.com
PMV Pharmaceuticals Reports Second Quarter 2025 Financial Results and Corporate Highlights
PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of…
1 year ago globenewswire.com
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences
PRINCETON, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule,…
-
1 year ago benzinga.com
PMV Pharma Q1 EPS $(0.34) Beats $(0.37) Estimate
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.37) by 8.11 percent. This is a 13.33 percent decrease over losses of $(0.30)…
-
1 year ago benzinga.com
HC Wainwright & Co. Reiterates Buy on PMV Pharma, Maintains $5 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and maintains $5 price target.
-
1 year ago benzinga.com
PMV Pharma FY 2024 GAAP EPS $(1.14) Misses $(1.08) Estimate
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(1.14) per share which missed the analyst consensus estimate of $(1.08) by 5.56 percent.
-
1 year ago benzinga.com
PMV Pharma Q3 EPS $(0.37) Misses $(0.35) Estimate
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.35) by 5.71 percent. This is a 8.82 percent decrease over losses of $(0.34)…
-
2 years ago benzinga.com
HC Wainwright & Co. Reiterates Buy on PMV Pharma, Maintains $5 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and maintains $5 price target.
-
2 years ago benzinga.com
PMV Pharma Q2 EPS $(0.02) Beats $(0.33) Estimate
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.33) by 93.94 percent. This is a 94.74 percent increase over losses of $(0.38)…
-
2 years ago benzinga.com
HC Wainwright & Co. Reiterates Buy on PMV Pharma, Maintains $5 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and maintains $5 price target.
-
2 years ago benzinga.com
Foundation Medicine and PMV Pharma Partner to Develop Genomic Profiling for TP53 Mutation Therapy, Targets TP53 Mutation in Advanced Cancers with Investigational Therapy Rezatapopt
Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ:PMVP, ", PMV Pharma", )))) today announced a partnership to develop Foundation Medicine's tissue-based comprehensive genomic profiling
-
2 years ago benzinga.com
HC Wainwright & Co. Reiterates Buy on PMV Pharma, Maintains $5 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates PMV Pharma (NASDAQ:PMVP) with a Buy and maintains $5 price target.
-
2 years ago benzinga.com
Craig-Hallum Initiates Coverage On PMV Pharma with Buy Rating, Announces Price Target of $6
Craig-Hallum analyst Albert Lowe initiates coverage on PMV Pharma (NASDAQ:PMVP) with a Buy rating and announces Price Target of $6.
-
2 years ago benzinga.com
PMV Pharma Q1 EPS $(0.30) Beats $(0.37) Estimate
PMV Pharma (NASDAQ:PMVP) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.37) by 18.92 percent. This is a 28.57 percent increase over losses of $(0.42)…